December 21, 2018 / 7:45 AM / a month ago

BRIEF-Cerenis Therapeutics Reports Results Of The Phase I Study Of Repeated And Increasing Doses To Assess CER-209 In NASH/NAFLD

Dec 21(Reuters) - CERENIS THERAPEUTICS HOLDING SA :

* REPORTED ON THURSDAY RESULTS OF THE PHASE I STUDY OF REPEATED AND INCREASING DOSES TO ASSESS CER-209 IN NASH/NAFLD

* ABSENCE OF ANY MAJOR ADVERSE EVENTS, CONFIRMING CER-209’S FAVORABLE SAFETY AND TOLERANCE PROFILE

* DAILY ADMINISTRATION OF INCREASING DOSES OF CER-209 OVER A 28-DAY PERIOD IN PATIENTS WITH A HIGH RISK OF NAFLD/NASH DEMONSTRATED PROPORTIONAL INCREASE IN CER-209 BLOOD LEVELS

* MECHANISM OF ACTION VIA THE P2Y13 RECEPTOR SUPPORTED BY CHANGES IN HDL CHOLESTEROL

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below